Close

Pre-Open Stock Movers 01/02: (PULM) (SAVA) (WATT) Higher; (DRRX) (SIG) Lower (more...)

January 2, 2020 9:25 AM EST

Today's pre-open stock movers:

Pulmatrix, Inc. (NASDAQ: PULM) 116.3% HIGHER; Announced that it has entered into a licensing and development agreement with the Lung Cancer Initiative at Johnson & Johnson*. Through the agreement, the Lung Cancer Initiative gains an option to access a portfolio of narrow spectrum kinase inhibitors intended for development in lung cancer interception.

DURECT Corporation (NASDAQ: DRRX) 34.2% LOWER; announced the results from its Phase 2a clinical trial of DUR-928 in patients with mild to moderate plaque psoriasis. Twenty-two patients completed the study, applying DUR-928 topically to the plaque on one arm and the vehicle (placebo) to a similar plaque on the other arm daily for 28 days.

Cassava Sciences (NASDAQ: SAVA) 33% HIGHER; CEO Remi Barbier disclosed a purchase of 100,000 shares at $5.53 on Dec. 31.

Energous Corporation (Nasdaq: WATT) 10.7% HIGHER; announced that its partners PiBEX, an R&D subsidiary of POSCO Worldwide, and SK Telesys are developing an ultra-wideband (UWB) tracking tag for POSCO, a Korean-based global steel manufacturer, which will include integration with the WattUp RF wireless charging technology. The POSCO UWB tracking tag enables location-tracking for security and employee safety purposes within industrial factories.

Abeona Therapeutics (NASDAQ: ABEO) 6.4% HIGHER; Director, Stefano Buono, disclosed the purchase of 200,000 shares made on 12/24 at $2.50 per share.
Signet Jewelers (NYSE: SIG) 4.3% LOWER; Wells Fargo downgraded from Equal Weight to Underweight with a price target of $12.00.
Fastly Inc. (NYSE: FSLY) 3.6% HIGHER; Piper Jaffray upgraded from Neutral to Overweight with a price target of $24.00.

Designer Brands (NYSE: DBI) 3.6% HIGHER; Wells Fargo analyst Tom Nikic upgraded from Equal Weight to Overweight with a price target of $20.00.

Mesoblast Limited (Nasdaq: MESO) 2% HIGHER; announced that the United States Food and Drug Administration (US FDA) has confirmed receipt of Mesoblasts filing of clinical efficacy and safety data for remestemcel-L in its rolling Biologics License Application (BLA) for the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD). The final module will be filed during January, and Mesoblast will request an expedited FDA review of the BLA under the product candidates existing Fast Track designation

Tesla, Inc. (Nasdaq: TSLA) 1.8% HIGHER; PT raised to 'Street High' $515 at Canaccord Genuity.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Special Reports

Related Entities

Piper Jaffray, Tesla, Wells Fargo, Canaccord Genuity, Pre-Open Losers, Pre-Open Winners, Pre Market Movers, FDA